Journal article
Liquid Biopsy Proteomics in Ophthalmology
Journal of proteome research, Vol.23(2), pp.511-522
02/02/2024
DOI: 10.1021/acs.jproteome.3c00756
PMCID: PMC10845144
PMID: 38171013
Abstract
Minimally invasive liquid biopsies from the eye capture locally enriched fluids that contain thousands of proteins from highly specialized ocular cell types, presenting a promising alternative to solid tissue biopsies. The advantages of liquid biopsies include sampling the eye without causing irreversible functional damage, potentially better reflecting tissue heterogeneity, collecting samples in an outpatient setting, monitoring therapeutic response with sequential sampling, and even allowing examination of disease mechanisms at the cell level in living humans, an approach that we refer to as TEMPO (Tracing Expression of Multiple Protein Origins). Liquid biopsy proteomics has the potential to transform molecular diagnostics and prognostics and to assess disease mechanisms and personalized therapeutic strategies in individual patients. This review addresses opportunities, challenges, and future directions of high-resolution liquid biopsy proteomics in ophthalmology, with particular emphasis on the large-scale collection of high-quality samples, cutting edge proteomics technology, and artificial intelligence-supported data analysis.
Details
- Title: Subtitle
- Liquid Biopsy Proteomics in Ophthalmology
- Creators
- Julian WolfJoel A Franco - Stanford UniversityRui Yip - Stanford UniversityMohamed Ziad Dabaja - University of CalgaryGabriel Velez - Stanford UniversityFel Liu - Brigham and Women's HospitalAlexander G Bassuk - University of IowaPrithvi Mruthyunjaya - Stanford UniversityAntoine DufourVinit B Mahajan
- Resource Type
- Journal article
- Publication Details
- Journal of proteome research, Vol.23(2), pp.511-522
- DOI
- 10.1021/acs.jproteome.3c00756
- PMID
- 38171013
- PMCID
- PMC10845144
- eISSN
- 1535-3907
- Grant note
- DOI: 10.13039/100000053, name: National Eye Institute, award: R01EY031360, R01EY031952, R01EY030151, P30EY026877; DOI: 10.13039/100001818, name: Research to Prevent Blindness; DOI: 10.13039/100018133, name: VitreoRetinal Surgery Foundation; DOI: 10.13039/100020710, name: Translational Research and Applied Medicine, School of Medicine, Stanford University; name: The Alan and Irene Adler Ocular Cancer Research Initiative; name: Stanford Center for Optic Disc Drusen
- Language
- English
- Electronic publication date
- 01/03/2024
- Date published
- 02/02/2024
- Academic Unit
- Neurology; Stead Family Department of Pediatrics; Iowa Neuroscience Institute; Neurology (Pediatrics)
- Record Identifier
- 9984539750202771
Metrics
6 Record Views